# NCT04526106 (NCT04526106)

> REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04526106
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Elevar Therapeutics
- Conditions: FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Fusion/Rearrangement; FGFR2 Gene Translocation; FGFR2 Gene Activation; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Other Solid Tumors, Adult
- Interventions: RLY-4008
- Enrollment: 490
- Primary outcome: Part 1 and Part 4: Number of patients with adverse events and serious adverse events
- Primary outcome: Part 1: Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RLY-4008
- Primary outcome: Part 2 and Part 3: Objective Response Rate (ORR) assessed by Independent Review Committee per RECIST v1.1
- Primary outcome: Part 4: Number of patients with dose interruptions
- Primary outcome: Part 4: Number of patients with dose reductions
- Primary outcome: Part 4: Number of patients with dose discontinuations

## Commentary we found

- X threads: 21

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct04526106

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04526106", "email": "<work email>"}; the inbox owner confirms by the emailed link.